The breakthrough in vitro transcribed (IVT) RNA technology that researchers used during the COVID-19 pandemic paved the way for mRNA vaccine development to treat other infectious diseases. During IVT vaccine production, researchers generate synthetic pathogen genome sequences in bulk. In this process, employing robust nucleic acid quality control testing is critical to check the purity and integrity of the final vaccine product.
Download this white paper from Agilent to learn about the history of vaccine development, milestones in mRNA research, and the role of electrophoresis systems in mRNA vaccine development.
For Research Use Only. Not for use in diagnostic procedures.